| HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study JWD Hearn, G AbuAli, CA Reichard, CA Reddy, C Magi-Galluzzi, ... The Lancet Oncology 17 (10), 1435-1444, 2016 | 131 | 2016 |
| Incidence, risk factors, and complications of postoperative delirium in elderly patients undergoing radical cystectomy MC Large, C Reichard, JTB Williams, C Chang, S Prasad, Y Leung, ... Urology 81 (1), 123-129, 2013 | 88 | 2013 |
| Association of HSD3B1 genotype with response to androgen-deprivation therapy for biochemical recurrence after radiotherapy for localized prostate cancer JWD Hearn, W Xie, M Nakabayashi, N Almassi, CA Reichard, ... JAMA oncology 4 (4), 558-562, 2018 | 60 | 2018 |
| HSD3B1 genotype and clinical outcomes in metastatic castration-sensitive prostate cancer JWD Hearn, CJ Sweeney, N Almassi, CA Reichard, CA Reddy, H Li, ... JAMA oncology 6 (4), e196496-e196496, 2020 | 57 | 2020 |
| HSD3B1 and response to a nonsteroidal CYP17A1 inhibitor in castration-resistant prostate cancer N Almassi, C Reichard, J Li, C Russell, J Perry, CJ Ryan, T Friedlander, ... JAMA oncology 4 (4), 554-557, 2018 | 55 | 2018 |
| Outcomes of very high‐risk prostate cancer after radical prostatectomy: validation study from 3 centers D Sundi, JJ Tosoian, YA Nyame, R Alam, M Achim, CA Reichard, J Li, ... Cancer 125 (3), 391-397, 2019 | 48 | 2019 |
| Intermediate-term outcomes for men with very low/low and intermediate/high risk prostate cancer managed by active surveillance YA Nyame, N Almassi, SC Haywood, DJ Greene, V Ganesan, C Dai, ... The Journal of Urology 198 (3), 591-599, 2017 | 42 | 2017 |
| 100% uric acid stone formers: what makes them different? C Reichard, BC Gill, C Sarkissian, S De, M Monga Urology 85 (2), 296-298, 2015 | 41 | 2015 |
| Radical prostatectomy or radiotherapy for high‐and very high‐risk prostate cancer: a multidisciplinary prostate cancer clinic experience of patients eligible for either treatment CA Reichard, KE Hoffman, C Tang, SB Williams, PK Allen, MF Achim, ... BJU international 124 (5), 811-819, 2019 | 40 | 2019 |
| Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma JJ Duplisea, RJ Mason, CA Reichard, R Li, Y Shen, SA Boorjian, ... Canadian Urological Association Journal 13 (2), 24, 2019 | 35 | 2019 |
| Ductal prostate cancers demonstrate poor outcomes with conventional therapies W Ranasinghe, DD Shapiro, H Hwang, X Wang, CA Reichard, ... European urology 79 (2), 298-306, 2021 | 26 | 2021 |
| Applying precision medicine to the active surveillance of prostate cancer CA Reichard, AJ Stephenson, EA Klein Cancer 121 (19), 3403-3411, 2015 | 24 | 2015 |
| Gut microbiome–dependent metabolic pathways and risk of lethal prostate cancer: prospective analysis of a PLCO cancer screening trial cohort CA Reichard, BD Naelitz, Z Wang, X Jia, J Li, MJ Stampfer, EA Klein, ... Cancer Epidemiology, Biomarkers & Prevention 31 (1), 192-199, 2022 | 22 | 2022 |
| Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancer J Baack Kukreja, TK Bathala, CA Reichard, P Troncoso, S Delacroix, ... Prostate cancer and prostatic diseases 23 (1), 172-178, 2020 | 20 | 2020 |
| Radical prostatectomy in metastatic castration-resistant prostate cancer: feasibility, safety, and quality of life outcomes CA Reichard, JR Gregg, MF Achim, AM Aparicio, CA Pettaway, LL Pisters, ... European urology 74 (2), 140-143, 2018 | 18 | 2018 |
| Anterior urethral valve associated with posterior urethral valves: report of 2 cases and review of the literature CN Tran, CA Reichard, D McMahon, A Rhee Urology 84 (2), 469-471, 2014 | 18 | 2014 |
| Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8‐10) prostate cancer treated primarily by radical prostatectomy LJ Wilkins, JJ Tosoian, CA Reichard, D Sundi, W Ranasinghe, R Alam, ... Cancer 127 (9), 1425-1431, 2021 | 15 | 2021 |
| Impact of 5α-reductase inhibitors on disease reclassification among men on active surveillance for localized prostate cancer with favorable features C Dai, V Ganesan, J Zabell, YA Nyame, N Almassi, DJ Greene, D Hettel, ... The Journal of Urology 199 (2), 445-452, 2018 | 15 | 2018 |
| Downgrading from biopsy grade group 4 prostate cancer in patients undergoing radical prostatectomy for high or very high risk prostate cancer W Ranasinghe, CA Reichard, YA Nyame, D Sundi, JJ Tosoian, L Wilkins, ... The Journal of Urology 204 (4), 748-753, 2020 | 14 | 2020 |
| Prognostic significance of a negative confirmatory biopsy on reclassification among men on active surveillance V Ganesan, C Dai, YA Nyame, DJ Greene, N Almassi, D Hettel, J Zabell, ... Urology 107, 184-189, 2017 | 12 | 2017 |
